The Lung-Brain Axis in Chronic Obstructive Pulmonary Disease-Associated Neurocognitive Dysfunction: Mechanistic Insights and Potential Therapeutic Options
- PMID: 40520003
- PMCID: PMC12160515
- DOI: 10.7150/ijbs.109261
The Lung-Brain Axis in Chronic Obstructive Pulmonary Disease-Associated Neurocognitive Dysfunction: Mechanistic Insights and Potential Therapeutic Options
Abstract
Chronic obstructive pulmonary disease (COPD) ranks as the third leading cause of global mortality, affecting 210 million individuals worldwide. Notably, 60% of COPD patients experience comorbid neurocognitive disorders. Importantly, patients with neurocognitive dysfunction often exhibit poor adherence to therapeutic interventions and medications, exacerbating their COPD morbidity and increasing hospitalization rates and mortality risk. This review explores the potential lung-brain axis in COPD, emphasizing that oxidative stress and inflammatory responses in the lungs can spread to the systemic circulation, thereby regulating in the blood-brain barrier (BBB) permeability and contributing to brain dysfunction. In addition, the role of hormone-based hypothalamic-pituitary-adrenal (HPA) axis in COPD progression is discussed. These cascading events can lead to neuronal deficits, altered glial cell function, and subsequent cognitive dysfunction. Furthermore, we provide a comprehensive overview of potential medications for treating COPD and its associated cognitive deficits, with a specific focus on anti-inflammatory and antioxidant therapies. This compilation serves as a pivotal foundation for the prevention and management of cognitive dysfunction in COPD.
Keywords: COPD-related neurocognitive disorders (COPD-NCDs); Chronic obstructive pulmonary disease (COPD); Inflammation; Lung-brain axis; Neurocognitive disorders; Oxidative stress..
© The author(s).
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Figures



Similar articles
-
Novel pharmacological strategies to treat cognitive dysfunction in chronic obstructive pulmonary disease.Pharmacol Ther. 2022 May;233:108017. doi: 10.1016/j.pharmthera.2021.108017. Epub 2021 Oct 7. Pharmacol Ther. 2022. PMID: 34626675 Review.
-
The immune-inflammatory responses on the hypothalamic-pituitary-adrenal axis and the neurovascular unit in perioperative neurocognitive disorder.Exp Neurol. 2025 Apr;386:115146. doi: 10.1016/j.expneurol.2025.115146. Epub 2025 Jan 11. Exp Neurol. 2025. PMID: 39805464 Review.
-
New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease.Clin Sci (Lond). 2019 Apr 12;133(7):885-904. doi: 10.1042/CS20180316. Print 2019 Apr 15. Clin Sci (Lond). 2019. PMID: 30979844 Free PMC article. Review.
-
Neuroinflammation-A Crucial Factor in the Pathophysiology of Depression-A Comprehensive Review.Biomolecules. 2025 Mar 30;15(4):502. doi: 10.3390/biom15040502. Biomolecules. 2025. PMID: 40305200 Free PMC article. Review.
-
COPD and stroke: are systemic inflammation and oxidative stress the missing links?Clin Sci (Lond). 2016 Jul 1;130(13):1039-50. doi: 10.1042/CS20160043. Clin Sci (Lond). 2016. PMID: 27215677 Free PMC article. Review.
References
-
- Cheng M, Yan X, Wu Y, Zeng Z, Zhang Y, Wen F. et al. Qingke Pingchuan granules alleviate airway inflammation in COPD exacerbation by inhibiting neutrophil extracellular traps in mice. Phytomedicine: international journal of phytotherapy and phytopharmacology. 2025;136:156283. - PubMed
-
- Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. The European respiratory journal. 2003;22:672–88. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical